In a randomized study, @entity11794 was compared with @entity2379 for the treatment of @entity3 in a total of 239 adults from 56 sites in 20 countries. This study provided a unique opportunity to assess the frequency and outcome of @entity3 caused by different Candida species worldwide, and the results are presented here. Efficacy was primarily assessed at the end of intravenous therapy using a modified intent-to-treat (MITT) analysis. This analysis was performed on 224 of the 239 @entity1 enrolled in the study. Attempts were made to collect baseline Candida isolates from all @entity1 for species identification at a central laboratory. @entity375 were identified to the species level using two commercial systems and microscopic examination. Viable baseline isolates were recovered from 210 of the 224 (94%) @entity1 included in the MITT analysis. @entity5132 was the most frequently isolated species in all regions and was responsible for 45% of cases overall. Nevertheless, the majority of cases of @entity281 were caused by non- albicans Candida species. In the USA and Canada, @entity7408 was the second most commonly isolated pathogen (18%). In contrast, @entity7409 and @entity9841 accounted for 55% of cases in Latin America. Outcomes were comparable for @entity1 treated with @entity11794 (74% overall; 64% and 80% for infections due to @entity5132 and non- albicans species) and @entity2379 (62% overall; 58% and 68% for infections due to @entity5132 and non- albicans species), and were generally similar across continents. The distribution of Candida species isolated from @entity1 enrolled in a clinical trial may not be representative of pathogens causing @entity3 in the general population. Nevertheless, our findings may affect the regional choice of empirical antifungal therapy for seriously ill @entity1 with suspected or documented @entity3 since different Candida species have varying susceptibility to conventional antifungal drugs.

Global distribution and outcomes for Candida species causing @entity3 : results from an international randomized double-blind study of @entity11794 versus @entity2379 for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9841 :: ('5482', 'Species') :: ['Candida tropicalis'] @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B'] @entity7408 :: ('5478', 'Species') :: ['Candida glabrata'] @entity7409 :: ('5480', 'Species') :: ['Candida parapsilosis'] @entity5132 :: ('5476', 'Species') :: ['Candida albicans'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive candidiasis'] @entity375 :: ('4932', 'Species') :: ['Yeasts'] @entity11794 :: ('MESH:C105417', 'Chemical') :: ['caspofungin']
@entity3 :: (MESH:D009362,Disease) :: ['invasive candidiasis']
